Sclerostin-Inhibitor Therapy and Cardiovascular Outcomes in CKD

confidence: medium · 3 sources

⚠
Working research — not a recommendation.

This page records what the evidence says a policy does, not what anyone should do about it. It has been synthesized from the cited sources but has not been independently reviewed.

What the evidence says

The most direct trial evidence on this topic comes from people without CKD. In the Phase III ARCH trial, adjudicated serious cardiovascular events (myocardial infarction, stroke and cardiovascular death) were more common with romosozumab than with alendronate in the first year of treatment: 2.5% vs 1.9%. Absolute rates were modest, and the ARCH population does not represent a CKD cohort. A separate meta-analysis of up to three RCTs reported a probable higher risk of cardiovascular events with romosozumab, without effect sizes in the extracted text. Later meta-analyses and post-marketing surveillance describe the absolute risk as low but possibly clinically relevant in high-risk groups, particularly people with recent myocardial infarction or stroke. These sources give no absolute numbers.

Genetic evidence points the same way. SOST variants that mimic sclerostin inhibition were associated with lower fracture and osteoporosis risk, which matches the therapeutic effect of romosozumab. The same variants were associated with higher risk of myocardial infarction and/or coronary revascularization and of major adverse cardiovascular events. They were also associated with higher risk of type 2 diabetes, higher systolic blood pressure and more central adiposity. A 2024 cis-Mendelian randomization study found that genetically predicted lower sclerostin was associated with excess coronary artery disease risk and adverse cardiometabolic biomarker profiles. The genetic design supports the direction, but the sources say causal interpretation remains uncertain. One source gives effect sizes for none of these outcomes.

For CKD specifically, the evidence is thin. Post hoc analyses of FRAME and ARCH indicate that romosozumab preserved efficacy and had an acceptable overall safety profile in women with mild-to-moderate CKD. These are unplanned subgroup analyses, and the extracted claim gives no cardiovascular event rates. Nothing on this page measures cardiovascular outcomes in advanced CKD. A review states that advanced CKD is a biologically distinct calcification state driven by mineral stress. It says extrapolation from general osteoporosis populations should remain cautious. It also says long-term safety beyond approved treatment courses remains uncertain in CKD.

On mechanism, a narrative review of mechanistic work suggests that local vascular SOST/sclerostin is upregulated under calcifying stress, especially in CKD-associated vascular calcification. The review proposes this may be a compensatory response to mineral stress rather than a simple pro-calcific driver. If so, blocking sclerostin could remove a protective signal. That reading fits the genetic association with higher coronary risk, but the review does not establish it. Whether the upregulation seen in experimental systems holds in human CKD vascular tissue is not shown here.

Where the evidence splits

The CKD subgroup finding (acceptable overall safety in mild-to-moderate CKD) sits alongside the ARCH finding of more serious cardiovascular events with romosozumab than with alendronate (2.5% vs 1.9%). The claims point to two differences. The CKD result is a post hoc subgroup analysis with likely small samples, and the ARCH population does not represent a CKD cohort. The sources do not say whether the two findings measure the same cardiovascular endpoint, so the split is only partly explained by the sources on this page. The subgroup claim also reports overall safety rather than cardiovascular events specifically, so the two may not conflict directly.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

Findings

Romosozumab increases serious cardiovascular events relative to alendronate in postmenopausal women with osteoporosis at high fracture risk

confidence — direction: highconfidence — magnitude: mediumconsensus: settled on direction in non-CKD populations; magnitude is low in absolute terms and not quantified in the meta-analyses.
mechanism
sclerostin inhibition. The sources do not establish how it produces cardiovascular events. One review proposes that vascular sclerostin may be a compensatory response.
effect
increase in adjudicated serious cardiovascular events (myocardial infarction, stroke, cardiovascular death) in year 1 of ARCH: 2.5% with romosozumab vs 1.9% with alendronate. A meta-analysis of up to three RCTs indicated a probable higher risk. Later meta-analyses and surveillance describe low absolute risk that may be clinically relevant in high-risk groups.
conditions / moderators
risk is described as most relevant in people with recent myocardial infarction or stroke. The ARCH population does not represent a CKD cohort. Effect sizes and confidence intervals for the meta-analytic findings are not given.

Genetic variants that mimic sclerostin inhibition increase coronary and major adverse cardiovascular event risk

confidence — direction: high for SOST variants; medium for genetically predicted sclerostin levelsconfidence — magnitude: low for SOST variants; medium for genetically predicted sclerostin levelsconsensus: the two genetic sources agree on direction; neither reports effect sizes here.
mechanism
lifelong lower sclerostin activity, proxied by SOST variants or by genetically predicted sclerostin levels.
effect
SOST variants were associated with higher risk of myocardial infarction and/or coronary revascularization and of major adverse cardiovascular events. Genetically predicted lower sclerostin was associated with excess coronary artery disease risk and adverse cardiometabolic biomarker profiles. Effect sizes are not given in the extracted claims.
conditions / moderators
replication in independent genetic cohorts and exclusion of pleiotropy are not established. Causal interpretation remains uncertain. The variants also lowered fracture and osteoporosis risk.

Genetic variants that mimic sclerostin inhibition increase type 2 diabetes risk, systolic blood pressure and central adiposity

confidence — direction: highconfidence — magnitude: lowconsensus: thin. One source reports it.
mechanism
not established in the sources. These are cardiometabolic associations of the same SOST variants.
effect
increased risk of type 2 diabetes; higher systolic blood pressure; increased central adiposity. Effect sizes are not given.
conditions / moderators
not established. The claims do not say whether these outcomes mediate the coronary association.

Romosozumab shows no measured adverse cardiovascular effect in the mild-to-moderate CKD subgroup of FRAME and ARCH

confidence — direction: lowconfidence — magnitude: lowconsensus: thin. One review reports it, and it sits uneasily with the non-CKD ARCH signal (see "Where the evidence splits").
mechanism
not established.
effect
efficacy preserved and overall safety profile described as acceptable in women with mild-to-moderate CKD. No cardiovascular event rates are given.
conditions / moderators
unplanned post hoc subgroup analysis; likely small CKD subgroups; limited generalizability to advanced CKD or male populations.

Vascular sclerostin expression increases under calcifying stress in CKD-associated vascular calcification

confidence — direction: mediumconfidence — magnitude: lowconsensus: thin. It rests on a narrative review of mechanistic studies.
mechanism
local SOST/sclerostin upregulation, which the review suggests may be a compensatory response to mineral stress rather than a simple pro-calcific driver.
effect
upregulation of vascular SOST/sclerostin expression. No magnitude is given.
conditions / moderators
whether upregulation in experimental systems holds in human CKD vascular tissue, and whether its net effect is compensatory or pro-calcific, are not established.

Cardiovascular safety of sclerostin inhibition in advanced CKD and over long treatment durations is unmeasured

confidence — direction: medium for the long-term safety gap; high for the CKD distinctionconfidence — magnitude: lowconsensus: thin. The sources acknowledge an evidence gap and report no data.
mechanism
a review states that advanced CKD is a biologically distinct calcification state driven by mineral stress. Extrapolating from general osteoporosis populations should therefore be cautious.
effect
no measured effect reported; safety unknown.
conditions / moderators
applies to advanced CKD, and beyond approved treatment courses in CKD, diabetes or concurrent cardiovascular disease.